{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:33:35Z","timestamp":1786980815928,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Stealth BioTherapeutics, Inc."},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["PO1 HL074237-10 and 1RO1HL132154-01A1"],"award-info":[{"award-number":["PO1 HL074237-10 and 1RO1HL132154-01A1"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10557-018-6805-y","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T02:41:41Z","timestamp":1530067301000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide"],"prefix":"10.1007","volume":"32","author":[{"given":"Hani N.","family":"Sabbah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh C.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita","family":"Singh-Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Lanfear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"6805_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1139\/cjpp-2014-0060","volume":"92","author":"S Givvimani","year":"2014","unstructured":"Givvimani S, Pushpakumar S, Veeranki S, Tyagi SC. Dysregulation of Mfn2 and Drp-1 proteins in heart failure. Can J Physiol Pharmacol. 2014;92:583\u201391.","journal-title":"Can J Physiol Pharmacol"},{"key":"6805_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00109-014-1237-z","volume":"93","author":"MA Frohman","year":"2015","unstructured":"Frohman MA. Role of mitochondrial lipids in guiding fission and fusion. Mol Med. 2015;93:263\u20139.","journal-title":"Mol Med"},{"key":"6805_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/cvr\/cvp181","volume":"84","author":"L Chen","year":"2009","unstructured":"Chen L, Gong Q, Stice JP, Knowlton AA. Mitochondrial OPA1, apoptosis, and heart failure. Cardiovasc Res. 2009;84:91\u20139.","journal-title":"Cardiovasc Res"},{"key":"6805_CR4","first-page":"141","volume":"148","author":"VG Sharov","year":"1996","unstructured":"Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 1996;148:141\u20139.","journal-title":"Am J Pathol"},{"key":"6805_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0033-0620(98)80003-0","volume":"40","author":"HN Sabbah","year":"1998","unstructured":"Sabbah HN, Sharov VG. Apoptosis in heart failure. Prog Cardiovasc Dis. 1998;40:549\u201362.","journal-title":"Prog Cardiovasc Dis"},{"key":"6805_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1124\/jpet.102.040147","volume":"304","author":"K Zhao","year":"2003","unstructured":"Zhao K, Luo G, Zhao GM, Schiller PW, Szeto HH. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide. J Pharmacol Exp Ther. 2003;304:425\u201332.","journal-title":"J Pharmacol Exp Ther"},{"key":"6805_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1083\/jcb.200906098","volume":"186","author":"RM DeVay","year":"2009","unstructured":"DeVay RM, Dominguez-Ramirez L, Lackner LL, Hoppins S, Stahlberg H, Nunnari J. Coassembly of Mgm1 isoforms requires cardiolipin and mediates mitochondrial inner memberane fusion. J Cell Biol. 2009;186:793\u2013803.","journal-title":"J Cell Biol"},{"key":"6805_CR8","doi-asserted-by":"publisher","first-page":"17589","DOI":"10.1074\/jbc.M111.330167","volume":"287","author":"AS Joshi","year":"2012","unstructured":"Joshi AS, Thompson MN, Fei N, Huttemann M, Greenberg ML. Cardiolipin and mitochondrial phosphatidylethanolamine have overlapping functions in mitochondrial fusion in Saccharomyces cerevisiae. J Biol Chem. 2012;287:17589\u201397.","journal-title":"J Biol Chem"},{"key":"6805_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bbabio.2015.03.007","volume":"1847","author":"LA Luevano-Martinez","year":"2015","unstructured":"Luevano-Martinez LA, Forni MF. Tiago dios Santios V, Souza-Pinto NC, Kowaltowski AJ. Cardiolipin is a key determinant for mtDNA stability and segregation during mitochondrial stress. Biochim Biophys Acta. 2015;1847:587\u201398.","journal-title":"Biochim Biophys Acta"},{"key":"6805_CR10","doi-asserted-by":"publisher","first-page":"34682","DOI":"10.1074\/jbc.M402999200","volume":"279","author":"K Zhao","year":"2004","unstructured":"Zhao K, Zhao GM, Wu D, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death. and reperfusion injury. J Biol Chem. 2004;279:34682\u201390.","journal-title":"and reperfusion injury. J Biol Chem"},{"key":"6805_CR11","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1681\/ASN.2012121216","volume":"24","author":"AV Birk","year":"2013","unstructured":"Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250\u201361.","journal-title":"J Am Soc Nephrol"},{"key":"6805_CR12","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1007\/s11095-011-0476-8","volume":"28","author":"HH Szeto","year":"2011","unstructured":"Szeto HH, Schiller PQ. Novel therapies targeting inner mitochondrial membrane\u2014from discovery to clinical development. Pharm Res. 2011;28:2669\u201379.","journal-title":"Pharm Res"},{"key":"6805_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1152\/japplphysiol.00471.2013","volume":"115","author":"EE Talbert","year":"2013","unstructured":"Talbert EE, Smuder AJ, Min K, Kwon OS, Szeto HH, Powers SK. Immobilization-induced activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted antioxidant. J Appl Physiol (1985). 2013;115:529\u201338.","journal-title":"J Appl Physiol (1985)"},{"key":"6805_CR14","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1089\/ars.2009.2445","volume":"11","author":"L Yang","year":"2009","unstructured":"Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal. 2009;11:2095\u2013104.","journal-title":"Antioxid Redox Signal"},{"key":"6805_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1074248413508003","volume":"19","author":"DA Brown","year":"2014","unstructured":"Brown DA, Hale SL, Baines CP, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide Bendavia. J Cardiovasc Pharmacol Ther. 2014;19:121\u201332.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"6805_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/FJC.0000000000000155","volume":"64","author":"W Dai","year":"2014","unstructured":"Dai W, Shi J, Gupta RC, Sabbah HN, Hale SL, Kloner RA. Bendavia, a mitochondria-targeting peptide, improves postinfarction cardiac function, prevents adverse left ventricular remodeling, and restores mitochondria-related gene expression in rats. J Cardiovasc Pharmacol. 2014;64:543\u201353.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6805_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/clpt.2014.174","volume":"96","author":"HH Szeto","year":"2014","unstructured":"Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity. Clin Pharmacol Ther. 2014a;96:672\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"6805_CR18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","volume":"171","author":"HH Szeto","year":"2014","unstructured":"Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014b;171:2029\u201350.","journal-title":"Br J Pharmacol"},{"key":"6805_CR19","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1096\/fj.12-220764","volume":"27","author":"V Righi","year":"2013","unstructured":"Righi V, Constantinou C, Mintzopoulos D, et al. Mitochondria-targeted antioxidant promotes recovery of skeletal muscle mitochondrial function after burn trauma assessed by in vivo 31P nuclear magnetic resonance and electron paramagnetic resonance spectroscopy. FASEB J. 2013;27:2521\u201330.","journal-title":"FASEB J"},{"key":"6805_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/acel.12102","volume":"12","author":"MP Siegel","year":"2013","unstructured":"Siegel MP, Kruse SE, Percival JM, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetic and skeletal muscle performance in aged mice. Aging Cell. 2013;12:763\u201371.","journal-title":"Aging Cell"},{"key":"6805_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/CCM.0b013e3182190b62","volume":"39","author":"SK Powers","year":"2011","unstructured":"Powers SK, Hudson MB, Nelson WB, et al. Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness. Crit Care Med. 2011;39:1749\u201359.","journal-title":"Crit Care Med"},{"key":"6805_CR22","doi-asserted-by":"publisher","first-page":"e002206","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206","volume":"9","author":"HN Sabbah","year":"2016","unstructured":"Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9:e002206.","journal-title":"Circ Heart Fail"},{"key":"6805_CR23","first-page":"H1379","volume":"260","author":"HN Sabbah","year":"1991","unstructured":"Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolisations. Am J Physiol. 1991;260:H1379\u201384.","journal-title":"Am J Physiol"},{"key":"6805_CR24","doi-asserted-by":"publisher","first-page":"654198","DOI":"10.1155\/2014\/654198","volume":"2014","author":"Q He","year":"2014","unstructured":"He Q, Harris N, Ren J, Han X. Mitochondria-targeted antioxidant prevents cardiac dysfunction induced by tafazzin gene knockdown in cardiac myocytes. Oxid Med Cell Longev. 2014;2014:654198.","journal-title":"Oxid Med Cell Longev"},{"key":"6805_CR25","first-page":"2198645","volume":"2016","author":"HJ Liu","year":"2016","unstructured":"Liu HJ, Liao H-H, Yang Z, Tang Q-Z. Peroxisome proliferator-activated receptor-\u03b3 is critical to cardiac fibrosis. PPAR Res. 2016;2016:2198645.","journal-title":"PPAR Res"},{"key":"6805_CR26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1128\/MCB.00911-10","volume":"31","author":"KN Papanicolaou","year":"2011","unstructured":"Papanicolaou KN, Dhairallah RJ, Ngoh GA, et al. Mifofusion-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol Cell Biol. 2011;31:1309\u201328.","journal-title":"Mol Cell Biol"},{"key":"6805_CR27","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1681\/ASN.2014080750","volume":"26","author":"M Sumida","year":"2015","unstructured":"Sumida M, Doi K, Ogasawara E, et al. Regulation of mitochondrial dynamics of dynamin-related protein-1 in acute cardiorenal syndrome. J Am Soc Nephrol. 2015;26:2378\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"6805_CR28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1126\/science.1231031","volume":"340","author":"Y Chen","year":"2013","unstructured":"Chen Y. Dorn GW-II. PINK1-phosphorylated mitofusion 2 is a Parkin receptor for culling damaged mitochondria. Science. 2013;340:471\u20135.","journal-title":"Science."},{"key":"6805_CR29","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1091\/mbc.e04-08-0697","volume":"16","author":"GB John","year":"2005","unstructured":"John GB, Shang Y, Renken C, et al. The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell. 2005;16:1543\u201354.","journal-title":"Mol Biol Cell"},{"key":"6805_CR30","doi-asserted-by":"publisher","first-page":"R186","DOI":"10.1152\/ajpregu.00423.2010","volume":"300","author":"WA Baseler","year":"2011","unstructured":"Baseler WA, Dabkowski ER, Williamson CL, et al. Proteomic alterations of distinct mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import dysfunction. Am J Physiol Regul Integr Comp Physiol. 2011;300:R186\u2013200.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"6805_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/0022-2828(92)93098-5","volume":"24","author":"HN Sabbah","year":"1992","unstructured":"Sabbah HN, Sharov VG, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1992;24:1333\u201347.","journal-title":"J Mol Cell Cardiol"},{"key":"6805_CR32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1006\/jmcc.1998.0739","volume":"30","author":"VG Sharov","year":"1998","unstructured":"Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 1998;30:1757\u201362.","journal-title":"J Mol Cell Cardiol"},{"key":"6805_CR33","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1161\/CIRCHEARTFAILURE.113.000406","volume":"6","author":"D-F Dai","year":"2013","unstructured":"Dai D-F, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, et al. Global proteomics and pathway analysis of pressure-overload\u2013induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ Heart Fail. 2013;6:1067\u201376.","journal-title":"Circ Heart Fail"},{"key":"6805_CR34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.kint.2016.10.036","volume":"91","author":"MT Sweetwyne","year":"2017","unstructured":"Sweetwyne MT, Pippin JW, Eng DG, Hudkins KL, Chiao YA, Campbell MD, et al. The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney Int. 2017;91:1126\u201345.","journal-title":"Kidney Int"},{"key":"6805_CR35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1681\/ASN.2010080808","volume":"22","author":"HH Szeto","year":"2011","unstructured":"Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, et al. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22:1041\u201352.","journal-title":"J Am Soc Nephrol"},{"key":"6805_CR36","doi-asserted-by":"publisher","first-page":"F970","DOI":"10.1152\/ajprenal.00697.2013","volume":"306","author":"S Liu","year":"2014","unstructured":"Liu S, Soong Y, Seshan SV, Szeto HH. Novel cardiolipin therapeutic protects endothelial mitochondria during renal ischemia and mitigates microvascular rarefaction, inflammation. and fibrosis. Am J Physiol Renal Physiol. 2014;306:F970\u201380.","journal-title":"and fibrosis. Am J Physiol Renal Physiol."},{"key":"6805_CR37","doi-asserted-by":"crossref","unstructured":"Zhao H, Li H, Hao S, Chen J, Wu J, Song C, Zhang M, Qiao T, Li K. Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia. Sci Rep. 2017;7:9840 (1\u201311).","DOI":"10.1038\/s41598-017-10320-2"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6805-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T06:30:28Z","timestamp":1589697028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["6805"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6805-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"27 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Henry Ford Health System Institutional Animal Care and Use Committee and conforms to the <i>Guide for the Care and Use of Laboratory Animals<\/i> published by the US National Institutes of Health (NIH Publication No. 85\u201323, revised 1985).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Sabbah has received research grants from Stealth BioTherapeutics, Inc. and is a consultant for Stealth BioTherapeutics, Inc. Drs. Gupta, Singh-Gupta, Zhang and Lanfear have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures of Potential Conflicts of Interest"}}]}}